*Departments of Paediatrics, University “La Sapienza” of Rome, Italy
†University of Turin, Italy
‡University of Padua, Italy
§Niguarda Hospital of Milan, Italy
¶S. Antonio Abate Hospital of Gallarate, Italy
††University of Naples Federico II, Italy
‡‡University of Trieste, Italy
§§University of Messina, Italy, Italy
||Departments of Surgical Sciences, Italy
**Experimental Medicine and Pathology, University “La Sapienza” of Rome, Rome, Italy
Received 28 May, 2007
Accepted 26 January, 2008
Address correspondence and reprint requests to Margherita Bonamico, MD, PhD, Dipartimento di Pediatria, Via le Regina Elena 324, Rome 00161, Italy (e-mail: firstname.lastname@example.org).
Società Italiana di Gastroenterologica, Epatologia, e Nutrizione Pediatrica members are Clara Perricone, Antonella Castronovo, Silvia Conte, Sabrina Pigni, Erasmo Miele, Stefano Martelossi, and Concetta Sferlazzas.
Supported, in part, by grant C26A052433 2000–2004, “Anticorpi anti-transglutaminasi tissutale nella diagnosi e nel follow-up della malattia celiaca,” from the Italian University Public Education and Research Ministry, and by Italian Health Ministry grant ICS030.2/RF00.259 2001–2002, “Celiachia: sviluppo di linee guida per lo screening e la diagnosi e studio dei meccanismi patogenetici.”
The authors report no conflicts of interest.
Celiac disease (CD) is an autoimmune disorder characterized by a gluten-dependent enteropathy. The characteristic lesions (increase of intraepithelial lymphocytes, crypt hyperplasia, and villous atrophy) are generally searched for in the distal duodenum or proximal jejunum, according to the 1970 recommendation of the European Society for Paediatric Gastroenterology (1). Twenty years later, the Working Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) (2) recommended carrying out the small intestinal mucosal biopsy “always with a biopsy capsule rather than through an endoscope,” to obtain adequate specimens for histological examination, and the use of endoscopic grasp forceps was discouraged. The more recent guideline of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) suggests that “multiple endoscopic biopsies should be obtained from the more distal segments of the duodenum” for the presence of Brunner gland, which could interfere in the evaluation of the villous crypt ratio in the proximal duodenum (3,4).
We have demonstrated for the first time that at the diagnosis of CD, the histologically characteristic lesions are also present in the bulbar area; in 4 cases of 95, the bulbous mucosa was the only area affected by this enteropathy (5).
To throw a definitive light on this topic, we decided to perform a multicentre study with the following aims:
1. To verify, in a larger number of children with CD, whether histological lesions in CD are always present in the bulb mucosa
2. To evaluate the prevalence in children with CD who show lesions only in the duodenal bulb
3. To investigate whether CD-related mucosal lesions are present in the duodenal bulb mucosa of subjects submitted to upper endoscopy who are not affected by CD.
MATERIALS AND METHODS
We studied 665 children and adolescents with CD (241 males and 424 females, ages 9 months–15 years, 8 months, median age 5 years, 3 months) living in various Italian regions (group 1). The first 95 patients with CD had been collected in the Paediatric Department of the University “La Sapienza” of Rome (5); the other patients were enrolled consecutively from September 2003 to September 2005 under the auspices of the Italian Society of Paediatric Gastroenterology, Hepatology, and Nutrition from various centers in the northern, central, southern, and insular Italian regions, thus making our sample fairly representative of the entire Italian population. CD was diagnosed according to the revised ESPGHAN (2) and NASPGHAN (3) criteria.
A total of 348 children and adolescents also were enrolled (179 males and 169 females, ages 9 months–16 years, 4 months, median age 6 years, 2 months) as a control group. They underwent upper endoscopy for failure to thrive, abdominal pain, or vomiting, but their results did not indicate CD (group 2).
The screening tests included total immunoglobulin (Ig) A; IgA and IgG anti-gliadin antibodies, tested by an enzyme-linked immunosorbent assay (Alfagliatest, Eurospital, Trieste, Italy); IgA and IgG anti-endomysium antibodies (EMA), tested by an indirect immunofluorescence method (Eurospital) using as substrate sections from the distal portion of monkey's esophagus; IgA and IgG anti-tissue transglutaminase autoantibodies (anti-tTGAbs) evaluated with an enzyme-linked immunosorbent assay (Eurospital and Menarini, Firenze, Italy) or with a quantitative radioimmunoprecipitation assay using human recombinant 35S-methionine–labeled tTG (6).
Human leukocyte antigen-DRB1, -DQA1, and -DQB1 genes were typed by polymerase chain reaction sequence–specific primers using commercial kits (Dynal, Bromborough, UK).
After fasting overnight, all of the patients underwent upper endoscopy with multiple biopsies following sedation or narcosis. An Olympus (Melville, NY) XP 10 gastroscope was used in children younger than 5 years, and an Olympus GIF E was used in older children. During each endoscopy, 1 sample from the duodenal bulb and 3 or 4 samples from the distal duodenum were taken.
To obtain a well-oriented sample, we laid each biopsy on filter paper and oriented it so that the luminal surface was uppermost. Each bioptic sample was fixed in 10% formalin and separately embedded in paraffin blocks. The sections were serially cut, stained with hematoxylin and eosin, and assessed under light microscopy. The histological adequacy of samples was assessed as described by Branski et al (7) and by Gottrand et al (8).
The histological lesions of the intestinal mucosa were evaluated according to the Marsh classification, as modified by Oberhuber et al (9): type 0 = normal mucosa; type 1 = infiltrative (with ≥40 intraepithelial lymphocytes/100 epithelial cells); type 2 = crypt hyperplasia; type 3a = mild villous atrophy; type 3b = marked villous flattening; and type 3c = total villous atrophy.
Immunohistochemistry with anti-CD3 monoclonal antibody (Dako, Copenhagen, Denmark) was performed in 306 patients representative of all of the participating groups. According to the review of Dickson et al (10), we considered 30 intraepithelial lesions (IELs)/100 epithelial cells to be the normal value.
A gluten-free diet was suggested for patients with CD and a clinical and serological follow-up was initiated; in patients who did not show diffuse lesions of the intestinal mucosa, DQ2/DQ8 heterodimers were typed and a second biopsy was suggested after 1 year of a gluten-free diet. The study was performed according to the Declaration of Helsinki. Informed consent was obtained from the parents for their children.
All 665 children and adolescents with CD (group 1) showed mucosal changes compatible with CD in the duodenal bulb. Of them, 16 (2.4%), 5 boys and 11 girls, ages 1 year, 8 months to 12 years, 11 months (median age 6 years, 7 months) had histological lesions in the duodenal bulb, but a typical-appearing mucosa in the distal duodenum (group 1A); CD3 count of biopsies of the distal duodenum was always <30 IELs. Patchy villous atrophy was detected in 20 (3%) patients, 8 boys and 12 girls, ages 1 year, 8 months to 16 years (median age 6 years, 2 months) (group 1B).
As reported in Table 1, all of the group 1A and group 1B children were EMA and/or anti-tTGAbs positive; 18 of 19 (95%) patients carried the DQ2 and/or DQ8 heterodimers. Only 2 of 36 group 1A and group 1B patients (CD relatives) were clinically silent.
Diffuse histological lesions were present in all of the remaining patients with CD (group 1C). The types of lesions observed on the bulb, according to the Marsh modified classification (9), in the 3 groups of patients with CD, are shown in Table 2. In particular, type 1 lesions (Fig. 1) were detected in 1 of group 1A and group 1B and in 23 group 1C patients; type 2 lesions were present in 1 group 1A and in 19 group 1C subjects. Overall, the most frequent lesions present in the 3 groups were the most severe degrees of villous atrophy (Oberhuber types 3b and 3c) as shown in Figures 2 and 3, respectively. None of the 348 nonceliac gastroenterological controls (group 2) had similar mucosal changes in the duodenal bulb.
The follow-up of group 1A and 1B patients showed the disappearance of CD-related symptoms and the normalization of serum autoantibodies. In 7 of 16 group 1A children (including the 2 patients with type 1 and 2 lesions) and in 5 of 20 group 1B children, who underwent a control biopsy after 1 year or more following the start of a gluten-free diet, the mucosa showed a normal histological aspect. In particular, the DQ2-/DQ8- patient belonging to group 1B was EMA positive, and antibodies became negative after 6 months of a gluten-free diet. Permission for a second biopsy was denied by the parents.
We already have demonstrated (5) that bulbar mucosa in children with CD always shows CD-related histological alterations; sometimes this mucosa is the only one affected at the diagnosis of the disease, and not only during gluten challenge, as Vogelsang et al (11) reported in 2 adult females.
To confirm these data, we decided to enlarge the previous series of 95 children and adolescents to achieve a statistically significant number of subjects. We collected 570 more children and adolescents, with a total number of 665 from 8 Italian centers, and all of them showed some degree of histological lesions in the bulb mucosa.
The results of the multicenter study confirm our previous observation (5) that in CD, histological lesions always are present in the bulb mucosa. In a remarkable percentage (2.5%) of patients, this area was the only one affected. In these patients, all of the samples taken in the distal duodenum showed normal villi and the count of IELs, made by CD3, was always <30 lymphocytes/100 epithelial cells. Recently, many studies on IEL counts have been published; however, to date, there is no agreement about the choice of cutoff value for normal subjects. Some papers proposed a normal value lower than 25 lymphocytes/100 epithelial cells (12,13). Other authors described an increase of duodenal IELs in association with mucosal changes that mimic CD (14–16). In the present study, in accordance with the recent review of Dickson et al (10), we have chosen the cutoff of 30 IELs/100 epithelial cells.
Isolated bulb lesions have also been reported by Brocchi et al (17), in a symptomatic adult female patient with negative serology. Also, Ravelli et al (18) in a recent study reported on 110 children with CD, all of them presenting with histological lesions in the duodenal bulb. Interestingly, in these patients total villous atrophy was found more frequently in the distal duodenum and the proximal jejunum than in more proximal areas. A possible explanation has not been provided.
The histological lesions in the duodenal bulb could be explained by the fact that this intestinal portion is particularly rich in lymphatic structures (4) and the first one to be reached by gluten (11). We can speculate that patients considered to potentially have CD could have isolated bulbar lesion, but they did not undergo the bulbar biopsies.
The percentage of isolated bulb lesions in our multicenter study was lower (2.4%) than in our previous article (4.2%). In this study, there is evidence of the phenomenon in which enlarging the number of observations following a pilot study tends to decrease the prevalence of a particular variable. The results of early pilot studies for other aspects of CD, such as the association with Down syndrome and Turner syndrome, including the former (19,20), were partially modified by enlarging the series (21,22).
The detection of villous atrophy patchily distributed in children is generally referred to as cow's milk protein intolerance (23), whereas its presence already is described in adults affected by CD (24). In the present multicenter study, we observed a patchy villous atrophy in a small percentage of children with CD, demonstrating that, although infrequent, the possibility of patchy distribution of mucosal lesion in this pathology must be taken into consideration.
The diagnosis of CD in our patients without diffuse lesions is supported by the clinical signs, prevalence of symptoms, and presence of CD-related autoantibodies. In fact, we found 88.9% of them were EMA positive and all of them were anti-tTGAbs positive, underlining the higher sensitivity of these last autoantibodies (25,26). In addition, the normalization of antibody serum levels on a gluten-free diet and of the bulb mucosa in patients undergoing intestinal biopsy, including those with Marsh type 1 and type 2 lesions, confirm the diagnosis of CD.
The absence of lesions suggesting CD in the duodenal bulb in all of the gastroenterological control subjects emphasizes the importance of performing intestinal biopsy in this area. We can suggest a useful diagnostic flowchart for CD diagnosis and for CD screening in subjects who undergo endoscopy for other reasons. If we suspect the disease (from the clinical observation, the serology, and the patient belonging to at-risk groups), then we advise taking multiple biopsies, at least 2 from the bulb and 2 from the distal duodenum in each endoscopic procedure. If the bioptic samples show CD-compatible lesions, then the gluten-free diet should be initiated. In addition, to avoid missing diagnosis of a silent form of CD (27), when upper endoscopies are performed for indications different from CD, we suggest taking at least 1 bioptic sample of bulb. In these patients, if we found CD-related bulbar lesions, then EMA and/or anti-tTGAbs would be evaluated, and in positive cases, gluten-free diet initiated. In fact, it is well known that undetected CD may cause many harmful complications: those related to malabsorption, such as iron-deficient anemia (28) and osteopathy (29), and those associated with the autoimmune process underlying the disease, such as type 1 diabetes mellitus (30) and thyreopathy (31). In addition, infertility (32), low-birth-weight infants (33), dilated cardiomyopathy (34), and other forms of heart failure (35) have been observed in patients with CD. Therefore, making an elusive diagnosis of celiac disease could compensate for the effort of performing an additional bulbar biopsy.
We are grateful to Barbara Mora and Claudio Tiberti for scientific collaboration. The authors also thank Mrs Patricia Byrne for help with writing in English.
1. Meeuwisse GW. Diagnostic criteria in coeliac disease. Acta Paediatr Scand 1970; 59:461–463.
2. Walker-Smith JA, Guandalini S, Schmitz J, et al
. Revised criteria for diagnosis of coeliac disease. Arch Dis Child 1990; 65:909–911.
3. Hill ID, Dirks MH, Liptak GS, et al
. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1–19.
4. Trier JS. Diagnostic value of peroral biopsy of the proximal small intestine. N Engl J Med 1971; 285:1470–1473.
5. Bonamico M, Mariani P, Thanasi E, et al
. Patchy villous atrophy of the duodenum in childhood celiac disease. J Pediatr Gastroenterol Nutr 2004; 38:204–207.
6. Bonamico M, Tiberti C, Picarelli A, et al
. Radioimmunoassay to detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for celiac disease. Am J Gastroenterol 2001; 96:1536–1540.
7. Branski D, Faber J, Shiner M. A comparison of small intestinal mucosal biopsies in children obtained by blind suction capsule with those obtained by endoscopy. J Pediatr Gastroenterol Nutr 1996; 22:194–196.
8. Gottrand F, Turck D, Mitchell V, et al
. Comparison of fiberendoscopy and Watson capsule for small intestinal biopsy in infants and children. Acta Paediatr 1992; 81:399–401.
9. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report for pathologists. Eur J Gastroenterol Hepatol 1999; 11:1185–1194.
10. Dickson BC, Streutker CJ, Chetty R. Coeliac disease: an update for pathologists. J Clin Pathol 2006; 59:1008–1016.
11. Vogelsang H, Hanel S, Steiner B, et al
. Diagnostic duodenal bulb biopsy in celiac disease. Endoscopy 2001; 33:336–340.
12. Hayat M, Cairns A, Dixon MF, et al
. Quantitation of intraepithelial lymphocytes in human duodenum: what is normal? J Clin Pathol 2002; 55:393–394.
13. Weress B, Franzen L, Bodin L, et al
. Duodenal intraepithelial lymphocyte-count revisited. Scand J Gastroenterol 2004; 39:138–144.
14. Memeo M, Jhang J, Hibshoosh H, et al
. Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori
gastritis. Mod Pathol 2005; 18:1134–1144.
15. Kakar S, Nehra V, Murray JA, et al
. Significance of intraepithelial lymphocytosis in small bowel biopsy samples with normal mucosal architecture. Am J Gastroenterol 2003; 98:2027–2033.
16. Goldstein NS. Proximal small-bowel mucosal villous intraepithelial lymphocytes. Histopathology 2004; 44:199–255.
17. Brocchi E, Tomassetti P, Volta U, et al
. Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. Eur J Gastroenterol Hepatol 2005; 17:1413–1415.
18. Ravelli A, Bolognini S, Gambarotti M, et al
. Variability of histologic lesions in relation to biopsy site in gluten-sensitive enteropathy. Am J Gastroenterol 2005; 100:177–185.
19. Bonamico M, Rasore Quartino A, Mariani P, et al
. Down syndrome and coeliac disease: usefulness of antigliadin and antiendomysium antibodies. Acta Pediatr 1996; 85:1503–1505.
20. Bonamico M, Bottaro G, Pasquino AM, et al
. Celiac disease and Turner syndrome. J Pediatr Gastroenterol Nutr 1998; 26:496–499.
21. Bonamico M, Mariani P, Danesi HM, et al
. Prevalence and clinical picture of celiac disease in Italian Down syndrome patients: a multicentre study. J Pediatr Gastroenterol Nutr 2001; 33:139–143.
22. Bonamico M, Pasquino AM, Mariani P, et al
. Prevalence and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab 2002; 87:5495–5498.
23. Manuel PD, Walker-Smith JA, France NE. Patchy enteropathy in childhood. Gut 1979; 20:211–215.
24. Scott BB, Losowsky MS. Patchiness and duodenal–jejunal variation of the mucosal abnormality in coeliac disease and dermatitis herpetiformis. Gut 1976; 17:984–992.
25. Bonamico M, Ferri M, Mariani P, et al
. Serological and genetic markers of celiac disease: a sequential study in the screening of first degree relatives. J Pediatr Gastroenterol Nutr 2006; 42:150–154.
26. Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment Pharmacol Ther 2006; 24:47–54.
27. Bottaro G, Cataldo F, Rotolo N, et al
. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol 1999; 94:691–696.
28. Bonamico M, Vania A, Monti S, et al
. Iron deficiency in children with celiac disease. J Pediatr Gastroenterol Nutr 1987; 6:702–706.
29. Gonzalez D, Mazure R, Mautalen C, et al
. Body composition and bone mineral density in untreated and treated patients with celiac disease. Bone 1995; 16:231–234.
30. Holmes GK. Screening for celiac disease in type 1 diabetes. Arch Dis Child 2002; 87:465–468.
31. Ansaldi N, Palmas T, Corrias A, et al
. Autoimmune thyroiditis and celiac disease in children. J Pediatr Gastroenterol Nutr 2003; 37:139–143.
32. Fergusson R, Holmes GK, Cooke WT. Coeliac disease, fertility, and pregnancy. Scand J Gastroenterol 1982; 17:65–68.
33. Ciacci C, Cirillo M, Auriemma G, et al
. Coeliac disease and pregnancy outcome. Am J Gastroenterol 1996; 91:718–722.
34. Prati D, Bardella MT, Peracchi M, et al
. High frequency of antiendomysial reactivity in candidates to heart transplant. Dig Liv Dis 2002; 34:39–43.
35. Frustaci A, Cuoco L, Chimenti C, et al
. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611–2620.
© 2008 Lippincott Williams & Wilkins, Inc.